TECN Stock Analysis: Tecan | SW
Medical Instruments & Supplies | SW, Switzerland | Market Cap: 2.384m CHF | 12M Return: 11.8% | CH0012100191 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 9.77M
Warnings
No concerns identified
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Tecan Group AG (TECN) is a Swiss-based provider of laboratory instruments and automation solutions serving the biopharmaceutical, forensic, and clinical diagnostics markets across Europe, North America, Asia, and other international regions. The company operates through two segments: Life Sciences Business and Partnering Business, offering products such as liquid handling and automation systems, microplate readers and washers, software, consumables, sequencing reagents, immunoassays, and antibodies. Its end-to-end automation solution is marketed as Tecan Labwerx.
In addition to its core instrument portfolio, Tecan offers contract design and manufacturing services through its PARAMIT business, which provides outsourced engineering and production for medical devices and life sciences instruments. The company has also established a strategic collaboration with NVIDIA Corporation to co-develop an AI-enabled platform aimed at improving data-driven laboratory workflows, research discoveries, and overall lab productivity. Tecan was founded in 1980 and is headquartered in Männedorf, Switzerland.
As a mid-cap company in the Health Care Equipment sub-industry, Tecan operates in the life sciences tools and laboratory automation sector, which supplies recurring revenue streams through consumables, reagents, and service contracts alongside its instrument sales. The Partnering Business model, which includes OEM and contract manufacturing arrangements, is a common approach in the broader medtech outsourcing industry, allowing instrument makers to scale production without expanding internal manufacturing capacity.
- Life Sciences segment growth driven by lab automation demand
- Biopharma end-market weakness pressures instrument order growth
- NVIDIA AI platform partnership opens new lab automation revenue stream
- Partnering Business OEM contract manufacturing expands with PARAMIT
| Net Income: -116.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -4.16 > 1.0 |
| NWC/Revenue: 42.60% < 20% (prev 33.94%; Δ 8.67% < -1%) |
| CFO/TA 0.06 > 3% & CFO 95.3m > Net Income -116.3m |
| Net Debt (57.7m) to EBITDA (98.1m): 0.59 < 3 |
| Current Ratio: 2.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (12.4m) vs 12m ago -3.42% < -2% |
| Gross Margin: 34.06% > 18% (prev 35.19%; Δ -1.13% > 0.5%) |
| Asset Turnover: 48.54% > 50% (prev 46.77%; Δ 1.78% > 0%) |
| Interest Coverage Ratio: 13.02 > 6 (EBIT TTM 40.1m / Interest Expense TTM 3.08m) |
| A: 0.23 (Total Current Assets 652.8m - Total Current Liabilities 281.9m) / Total Assets 1.65b |
| B: 0.58 (Retained Earnings 961.7m / Total Assets 1.65b) |
| C: 0.02 (EBIT TTM 40.1m / Avg Total Assets 1.79b) |
| D: 2.11 (Book Value of Equity 1.12b / Total Liabilities 530.1m) |
| Altman-Z'' = 5.74 = AAA |
| DSRI: 1.33 (Receivables 197.1m/153.8m, Revenue 870.5m/906.6m) |
| GMI: 1.03 (GM 35.19% / 34.06%) |
| AQI: 1.04 (AQ_t 0.53 / AQ_t-1 0.51) |
| SGI: 0.96 (Revenue 870.5m / 906.6m) |
| TATA: -0.13 (NI -116.3m - CFO 95.3m) / TA 1.65b) |
| Beneish M = -2.74 (Cap -4..+1) = A |
As of August 26, 2026, the stock is trading at CHF 192.70 with a total of 24,730 shares traded. Over the past week, the price has changed by +0.36%, over one month by +5.76%, over three months by +29.24% and over the past year by +11.76%.
Current recommended Stop Loss: 178.90 (which is 7.2% or 2 ATR below the current price).
Tecan has no consensus analysts rating.
P/E Forward = 27.3973
P/S = 2.6681
P/B = 2.1739
P/EG = 1.7068
Revenue TTM = 870.5m CHF
EBIT TTM = 40.1m CHF
EBITDA TTM = 98.1m CHF
Long Term Debt = 150.3m CHF (from longTermDebt, last fiscal year)
Short Term Debt = 20.2m CHF (from shortTermDebt, last quarter)
Debt = 282.3m CHF (from shortLongTermDebtTotal, last quarter) + Leases 68.0m
Net Debt = 57.7m CHF (calculated: Debt 282.3m - CCE 224.6m)
Enterprise Value = 2.44b CHF (2.38b + Debt 282.3m - CCE 224.6m)
Interest Coverage Ratio = 13.02 (Ebit TTM 40.1m / Interest Expense TTM 3.08m)
EV/FCF = 41.37x (Enterprise Value 2.44b / FCF TTM 59.0m)
FCF Yield = 2.42% (FCF TTM 59.0m / Enterprise Value 2.44b)
FCF Margin = 6.78% (FCF TTM 59.0m / Revenue TTM 870.5m)
Net Margin = -13.36% (Net Income TTM -116.3m / Revenue TTM 870.5m)
Gross Margin = 34.06% ((Revenue TTM 870.5m - Cost of Revenue TTM 574.0m) / Revenue TTM)
Gross Margin QoQ = 33.90% (prev 34.21%)
Tobins Q-Ratio = 1.48 (Enterprise Value 2.44b / Total Assets 1.65b)
Interest Expense / Debt = 1.09% (Interest Expense 3.08m / Debt 282.3m)
Taxrate = 22.05% (3.47m / 15.7m)
NOPAT = 31.2m (EBIT 40.1m * (1 - 22.05%))
Current Ratio = 2.32 (Total Current Assets 652.8m / Total Current Liabilities 281.9m)
Debt / Equity = 0.25 (Debt 282.3m / totalStockholderEquity, last quarter 1.12b)
Debt / EBITDA = 0.59 (Net Debt 57.7m / EBITDA 98.1m)
Debt / FCF = 0.98 (Net Debt 57.7m / FCF TTM 59.0m)
Total Stockholder Equity = 1.25b (last 4 quarters mean from totalStockholderEquity)
RoA = -6.49% (Net Income -116.3m / Total Assets 1.65b)
RoE = -9.33% (Net Income TTM -116.3m / Total Stockholder Equity 1.25b)
RoCE = 2.87% (EBIT 40.1m / Capital Employed (Equity 1.25b + L.T.Debt 150.3m))
RoIC = 2.33% (NOPAT 31.2m / Invested Capital 1.34b)
WACC = 8.64% (E(2.38b)/V(2.67b) * Re(9.56%) + D(282.3m)/V(2.67b) * Rd(1.09%) * (1-Tc(0.22)))
Discount Rate = 9.56% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -76.52 | Cagr: -1.83%
[DCF] Terminal Value 72.02% ; FCFF base≈95.5m ; Y1≈83.7m ; Y5≈67.6m
[DCF] Fair Price = 79.42 (EV 1.04b - Net Debt 57.7m = Equity 978.6m / Shares 12.3m; r=8.64% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: -96.04 | Revenue CAGR: -7.99% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=6.57 | Chg30d=+4.87% | Revisions=+50% | GrowthEPS=-4.4% | GrowthRev=+0.4%
EPS next Year (2027-12-31): EPS=7.74 | Chg30d=+0.52% | Revisions=+50% | GrowthEPS=+17.9% | GrowthRev=+5.3%
[Analyst] Revisions Ratio: +67% (up=6, down=0)